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Abstract 
Background: Little is known about the subsequent risk of stroke and recurrence of IE for patients 
surviving infective endocarditis (IE) with a residual vegetation at discharge. 
Methods: Patients were consecutively included in the East Danish Endocarditis Registry from 
2002-2012. We included patients undergoing medical treatment only during IE admission who were 
discharged alive. Size of residual vegetation was assessed by echocardiography at discharge and 
patients were categorized according to median length of residual vegetation. Using multivariable 
adjusted Cox Proportional hazard analysis, we assessed the associated risk of stroke and recurrence 
of IE between study groups.  
Results: Among 915 IE patients, 305 were included after selection criteria were applied, 151 
patients without residual vegetation, 73 patients with 1-5 mm residual vegetation, and 81 patients 
with >5 mm residual vegetation. We identified an increased associated risk of stroke for patients 
with 1-5 mm and >5 mm residual vegetation, HR=0.88 (95% CI: 0.26-2.94) and HR=2.95 (95% 
CI:1.18-7.34) compared with patients without residual vegetation. No difference was seen between 
groups for the associated risk of recurrence of IE, HR=1.39 (95% CI: 0.91-2.13) and HR=1.38 
(95% CI: 0.91-2.10) for patients with a residual vegetation 1-5 mm and >5 mm compared with 
patients without residual vegetation. 
Conclusions: Patients surviving IE with a residual vegetation >5 mm had an increased associated 
risk of stroke compared with patients without residual vegetation. These findings provide new 
perspectives on a patient group sparsely describe, suggesting a potential benefit of therapy among 
patients surviving IE with a residual vegetation >5 mm. 
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Introduction 
The mortality and morbidity in patients with infective endocarditis (IE) remains high and few 
studies have addressed the prognosis of patients surviving IE.[1,2] Vegetation size at time of 
diagnosis has been associated with an increased risk of embolic events and increased risk of 
mortality.[3] Little data are available on patients surviving IE with a residual vegetation and the 
subsequent risk of stroke and recurrence of IE. It is estimated that 20-40% of patients with IE 
experience a stroke[4] and vegetation size has been found to be a risk factor for cerebrovascular 
lesions and death.[3,5,6] To prevent embolic events during the course of IE, vegetation size may be 
an indication for surgery in patients with IE.[7] In patients surviving IE with residual vegetation, 
data on the associated risk of stroke and recurrence of IE could help clarify if these patients 
potentially could benefit from additional therapy after discharge e.g. antithrombotic treatment. The 
incidence of ischemic stroke in patients surviving IE have been estimated at 17.4 / 1,000 person 
years, which is more than 1.5 times higher compared with matched controls from the background 
population.[8] These data underline the need to address this issue in more detail.  
Recurrence of IE has been found to occur in 2.2% in a cohort from a referral center.[9] Recurrence 
of IE is a major concern since the prognosis of patients with recurrent IE is substantial worse 
compared with patients with first-time IE.[10] Still, few data underlines the American and European 
recommendations on short-term follow-up after IE.[7,11] In a scientific statement from the 
American Heart Association and in the current guidelines from the European Society of Cardiology 
(ESC) recommendations are regularly clinical and echocardiographic follow-up, particularly in the 
first year after discharge.[7,11] Data on patients with residual vegetation and the associated risk of 
subsequent stroke and recurrence of IE may help differentiate which patients should be followed 
more closely. The objective of this study was to investigate the associated risk of subsequent stroke 
and recurrence of IE in patients surviving IE by the size of residual vegetation. 
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Methods 
Data sources and study population 
The Danish health care system is universal and tax paid. Every Danish citizen is provided with a 
unique identifier making it possible to link clinical and administrative registries.[12] We used The 
East Danish Endocarditis Registry, which consecutively enrolled patients with IE from 2002-2012 
from Gentofte Hospital and Rigshospitalet (referral centers). As previously described, the registry 
holds information on demographic, clinical and paraclinical findings at baseline, bacterial etiology, 
surgical intervention, and echocardiographic data at hospitalization and discharge.[13] Further, we 
used The National Patient Registry, which holds information on every hospitalization in Denmark 
since 1977. The registry is derived from codes based on the International Classification of diseases 
(ICD) from discharge forms. The ICD-8 was used until 1994 and the ICD-10 was used 
subsequently. To identify patients with systemic arterial hypertension, we used antihypertensive 
medication from The National Prescription Registry. These registries has been characterized in 
details previously.[14,15] 
Echocardiography and size of vegetation 
Echocardiograms performed up to seven days prior to the date of discharge was considered as the 
discharge echocardiogram. In the absence of data from a transesophageal echocardiogram (TEE), 
the transthoracic echocardiogram (TTE) was used.  A residual vegetation was defined as an 
oscillating or non-oscillating intracardiac mass, as previously described.[16] The maximum length 
of the vegetation was used to evaluate the size of the vegetation. Data on left-sided valve 
regurgitation at IE discharge was available from the East Danish Endocarditis Registry. Severity of 
the regurgitation was assessed using a combination of qualitative, semi-quantitative, and 
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quantitative measures.[17] For patients with regurgitation of both the aortic and the mitral valve, the 
patient was categorized according to the most severe regurgitation. 
Study population  
The study population was derived from The East Danish Endocarditis Registry, including only 
patients with left-sided IE. We excluded 1) patients who died during IE-hospitalization, 2) patients 
who underwent surgery before discharge, 3) patients who did not have an echocardiogram 
performed at discharge, and 4) patients who had right-sided IE and pacemaker IE, see Figure 1 for 
the patient selection process. The study population was grouped in 1) patients without residual 
vegetation 2) patients with a residual vegetation below the median length of the vegetations (1-5 
mm), and 3) patients with a residual vegetation above the median length of the vegetations (>5 
mm). 
Covariates, endpoint and follow-up 
Patient characteristics at baseline were assessed at admission through medical records and patient 
interview. Atrial fibrillation before IE admission was assessed through the National Patient Registry 
with an in-hospital or out-patient diagnosis code in a period of up to ten years before IE admission. 
Systemic arterial hypertension was assessed as a confounding covariate, which was defined as 
antihypertensive through the National Prescription Registry with at least two filled prescriptions for 
antihypertensive medication within six months prior to IE admission, see Supplementary Table 1 
for specific codes. The primary endpoint of our study was stroke, which was identified from the 
National Patient Registry. Only a primary in-hospital diagnosis with one of the following ICD-10 
codes: I61-I64 was used. These codes have been validated with a positive predictive value between 
74% and 97% in the National Patient Registry.[18] Secondary endpoints were 1) recurrence of IE 
and 2) all-cause mortality. Recurrence of IE was identified from the National Patient Registry using 
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in-hospital, primary or secondary diagnosis code (ICD-10 codes: I33, I38, I398). Only patients with 
a length of hospital stay ≥14 days were included unless the patient died within 14 days of the 
hospital stay. The IE-codes have been validated with a positive predictive value of 90%.[19,20] 
Date of death was identified from The Cause of Death Registry. Heart valve surgery was considered 
as competing event and the National Patient Registry was used to identify heart valve surgery 
during follow-up (procedure codes: KFK [mitral valve surgery] and KFM [aortic valve surgery]).  
We followed patients from the date of IE discharge until date of: stroke, recurrence of IE, death, 
heart valve surgery, end of the study period (31 December 2016), or a maximum of five years of 
follow-up, whichever came first. 
Statistics 
Baseline characteristics were presented by study group (residual and no residual vegetation). 
Categorical variables were presented in counts and percentages, while continuous variables were 
presented with a median and 25 and 75 percentiles. Plots of the cumulative incidence of stroke and 
recurrence of IE were plotted for the two study groups using the Aalen-Johansen estimator. In the 
analysis of stroke we accounted for valve surgery, recurrence of IE, and death as a competing event 
and for recurrence of IE, valve surgery and death was accounted for as a competing event. Gray’s 
test was used to identify difference between curves. Kaplan-Meier plots were used to illustrate 
differences in mortality rate by the three groups. The log-rank test was used to identify difference 
between the Kaplan-Meier curves. Multivariable adjusted Cox proportional hazard analysis was 
used to identify the associated risk of stroke, recurrence of IE, and mortality in patients with 1-5 and 
>5 mm vegetation compared with no residual vegetation. The following covariates were included in 
the models investigating the associated risk of stroke and the risk of all-cause mortality: residual 
vegetation, chronic renal impairment, atrial fibrillation, diabetes mellitus, hypertension (defined 
from antihypertensive medication), prosthetic heart valve, sex and age. For the model investigating 
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the associated risk of recurrence of IE the following covariates were included: residual vegetation, 
chronic renal impairment, native heart valve disease, prosthetic heart valve, prior IE, causative 
microorganism, sex and age. Further, in an additional analysis, we examined the associated risk of 
IE relapse (within six months of follow-up) and the associated risk of recurrence of IE (beyond six 
months of follow-up). The proportional hazard was tested using Martingale’s residuals and if 
violated follow-up time was split in time intervals. Linearity was tested for continuous variables. 
We tested if there was an interaction with significant valve regurgitation (moderate or severe) and 
residual vegetation on recurrence of IE. In a supplementary analysis, residual vegetation was 
included as a continuous variable in the regression model. In a sensitivity analysis, we excluded 
patients with a prosthetic heart valve at the time of IE-diagnosis to account for the increased risk of 
stroke and IE compared with patients with native valves. Results were presented with a hazard ratio 
(HR) and a 95% CI. A p-value less than 0.05 was considered statistically significant. All statistical 
analyses were performed using the SAS statistical software, version 9.4 (SAS Institute, Inc., Cary, 
NC, USA) and RStudio. 
Results 
A total of 915 patients were screened from the East Danish Endocarditis Registry, including a total 
of 305 patients, 151 patients without a residual vegetation, 73 patients with a 1-5 mm residual 
vegetation, and 81 patients with a >5 mm residual vegetation, see Figure 1. The majority of patients 
were male with a similar median age between 68 and 70 years for all groups, Table 1. All patients 
had an echocardiography performed at IE discharge with over 95% of patients who had a TEE 
conducted at discharge. Patients without residual vegetation had more often a prosthetic heart valve 
and more often aortic valve IE compared with patients with 1-5 mm and >5 mm residual vegetation, 
Table 1. Patients with a residual vegetation 1-5 mm were more often on antihypertensive 
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medication compared with the two other groups, Table 1. Patients were followed for a median of 
3.6 years (25 and 75 percentiles: 0.7-5.0 years). 
Risk of stroke 
The cumulative risk of stroke at five years of follow-up was 6.6% (n=10), 5.5% (n=4) and 12.3% 
(n=10) for patients without residual vegetation, 1-5 mm vegetation, and >5 mm residual vegetation, 
respectively, Figure 2 (p=0.21 for difference between curves). In multivariable adjusted analyses we 
found an increased associated risk of stroke for patients with >5 mm residual vegetation compared 
with patients without a residual vegetation, Figure 3. No difference was seen between patients with 
a residual vegetation of 1-5 mm compared with patients without a residual vegetation, Figure 3. 
Including residual vegetation as a continuous variable in the multivariable adjusted regression 
model, we found an increased associated risk of stroke per one mm increase in residual vegetation, 
HR=1.08 (95% CI: 1.00-1.17). 
Recurrence of IE 
The cumulative risk of recurrence of IE with up to five years of follow-up was 16.0%, 11.0%, and 
18.5% in patients without residual vegetation, with 1-5 mm residual vegetation, and >5 mm residual 
vegetation, respectively, Supplemental Figure 1 (p-value=0.41 for difference between curves). In a 
multivariable adjusted analysis, we found no statistically significant difference in the associated risk 
of recurrence of IE for patients with a residual vegetation 1-5 mm and >5 mm, HR=0.66 (95% CI: 
0.29-1.53) and HR=1.34 (95% CI: 0.69-2.64) compared with patients without residual vegetation. 
We identified a non-significant associated risk of recurrence of IE when including residual 
vegetation as a continuous variable in the multivariable adjusted regression model, HR=1.04 (95% 
CI: 0.97-1.11). 
With up to six months of follow-up, we found a cumulative risk of 9.9% (95% CI: 5.8-15.3%), 
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8.2% (95% CI: 3.3-16.0%), and 9.9% (95% CI: 4.6-17.6%) for patients without residual, 1-5 mm 
residual vegetation, and >5 mm residual vegetation (p-value for difference in associated risk of IE 
relapse 0.49). Beyond six months of follow-up, we found a cumulative risk of IE of 7.5% (95% CI: 
3.7-13.2%), 3.4% (95% CI: 0.6-10.5%), and 6.9% (95% CI: 2.2-15.4%) for patients without 
residual, 1-5 mm residual vegetation, and >5 mm residual vegetation (p-value for difference in 
associated risk of IE recurrence 0.59). 
Mortality  
The five-year all-cause mortality rate was 40.3%, 54.0% and 50.9% for patients without residual 
vegetation, 1-5 mm residual vegetation, and >5 mm residual vegetation, respectively, Supplemental 
Figure 2 (p=0.09 for difference between curves). In a multivariable adjusted analysis, we found no 
statistically significant difference in mortality for patients with a 1-5 mm residual vegetation and >5 
mm residual vegetation, HR=1.39 (95% CI: 0.91-2.13) and HR=1.38 (95% CI: 0.91-2.10), 
respectively compared with patients without a residual vegetation. 
Regurgitation and valve surgery during follow-up 
We found that 40 patients (26.5%), 26 patients (35.6%), and 35 patients (43.2%) were discharged 
with a moderate or severe left-sided valve regurgitation among patients without residual vegetation, 
1-5 mm, and >5 mm residual vegetation, respectively, see Supplementary Table 2 for details on 
valve pathology. During follow-up, 11 patients (7.3%), 4 patients (5.5%), and 14 patients (17.3%) 
underwent left-sided heart valve surgery in patients without residual vegetation, 1-5 mm, and >5 
mm residual vegetation, see Supplementary Table 3. Significant valve regurgitation did not 
influence the effect of residual vegetation on the associated risk of recurrence of IE (p=0.61 for 
interaction). 
Sensitivity analysis 
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
In a sensitivity analysis, we excluded 114 patients with a prosthetic heart valve (47 patients with a 
mechanical heart valve and 67 patients with a bioprosthetic heart valve). We included 191 patients 
in the additional analysis; 82 patients (42.9%) without a residual vegetation, 51 patients (26.7%) 
with a 1-5 mm residual vegetation, and 58 patients (30.4%) with a >5 mm residual vegetation. In a 
multivariable adjusted analysis, we identified that patients with 1-5 mm was associated with a non-
significant increased risk of stroke, HR=2.89 (95% CI: 0.24-34.86), and >5 mm residual vegetation 
were associated with a significant increased risk of stroke, HR=11.91 (95% CI: 1.35-104.79) 
compared with patients without a residual vegetation. For recurrence of IE the estimates were: 
HR=1.03 (95% CI: 0.32-3.33) and HR=1.42 (95% CI: 0.54-3.76) for patients with a 1-5 mm and >5 
mm residual vegetation compared with no residual vegetation. For all-cause mortality the estimates 
were: HR=1.57 (95% CI: 0.89-2.76) and HR=1.29 (95% CI: 0.75-2.24) for patients with a 1-5 mm 
and >5 mm residual vegetation compared with no residual vegetation. 
Discussion 
We investigated patients surviving IE and the associated risk of stroke, recurrence of IE, and 
mortality in patients without residual vegetation, 1-5 mm, and >5 mm residual vegetation. Our 
study had three major findings, 1) patients with a residual vegetation >5 mm were associated with 
an increased risk of stroke compared with patients without a residual vegetation, 2) for every 
millimeter increase in residual vegetation, we identified a significant increased associated risk of 
stroke, 3) No difference was seen in the associated risk of recurrence of IE between groups. 
Patients treated for IE, who are clinically stable, can be discharged although residual vegetation 
exist, however the subsequent risk of stroke and recurrence of IE has remained unknown.[16] 
Several studies have investigated length of vegetation, measured in the initial phase of IE, and the 
associated risk of embolism in these patients.[3,21–23] All studies identified an increased 
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associated risk of embolism for patients with a vegetation length of >10 mm[21,23], >15 mm,[3] or 
≥30 mm[22] and cerebrovascular complications have been related to an increased mortality in IE 
patients.[5] Assessing vegetation length in the initial course of IE is a cornerstone in guidance of 
surgical therapy since vegetation length in the initial phase of IE is a risk factor of cerebrovascular 
events during the course of IE.[7] Up until now it has been unknown if a residual vegetation in 
patients surviving IE has increased the associated risk of subsequent stroke. Our results suggest an 
increased associated risk of stroke in patients with residual vegetation >5 mm compared with 
patients without residual vegetation. Platelet activation and thrombus generation around the 
vegetation may be an explanation to this finding and, speculatively, platelet inhibition may be 
beneficial in this patient group.     
We observed no significant differences in the risk of recurrence of IE for patients with 1-5 mm and 
>5 mm residual vegetation compared with patients without residual vegetation. One may have 
hypothesized that a residual vegetation may be a source of increased blood turbulence increasing 
the risk of recurrence of IE and. Our results on recurrence of IE may be underpowered and these 
results should be interpreted with caution. 
We identified a trend towards an increased mortality in the two patient groups with residual 
vegetation compared with patients without residual vegetation. A study by Thuny et al. identified an 
increased mortality for patients with a vegetation length >15 mm measured in the initial course of 
IE.[3] Differences between the results of Thuny et al. and our findings may be differences within 
the populations studied and the timing of echocardiographic assessment of the vegetation length. 
We only included patients undergoing medical treatment for IE and patients discharged with a 
vegetation >10 mm may have had an indication for surgery.[7] A high burden of comorbidities may 
be reflected in the clinical decision of not performing surgery in patients with a vegetation >10 mm, 
which could explain some of the difference seen in mortality rates between groups.  
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The ESC guidelines on IE states that patients treated for IE needs close clinical follow-up, 
especially in the first year after IE discharge.[7] Serial echocardiograms are suggested in the 
prevention of secondary heart failure and management of valve regurgitation follows ordinary 
guidelines on this subject.[7,17] However, specific guidance of how to manage patients with 
residual vegetation are not described. It has previously been shown that early surgery decrease the 
risk of a composite of embolic events and death in the acute phase of IE.[24] Our results provide 
new perspectives on these previous findings, suggesting a potential benefit of therapy among 
patients with a residual vegetation >5 mm. Cardiac surgery could potentially be conducted to 
remove the vegetation, however this approach may carry an even higher risk of stroke and adverse 
events in itself. 
Limitations and strengths 
Our study has some limitations. First, our study may be underpowered consequently leading to a 
type II error. Second, we are not able to identify if patients were discharged to hospice/palliative 
care or a nursery home. Third, more extensive echocardiography details would have added 
additional knowledge, such as the morphology of the residual vegetation. Fourth, data from brain 
imaging scans were not available from the registries. Such data could have helped describe the 
mechanism of stroke in detail. Fifth, laboratory values such as International Normalized Ratio 
(INR) subsequent to IE discharge was not available, which is important for patients with a 
mechanical prosthetic heart valve and the risk of stroke. 
Although limitations of this study exist, we believe the study has strengths as well. This study was 
able to combine a clinical registry with nationwide administrative registries allowing for clinical 
details with long-term follow-up from well-validated hospital codes on stroke and IE. The novelty 
of this combination gives unique insight to patients surviving IE, which has been sparsely described 
previously. 
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Conclusion 
Our results suggest that patients surviving IE with a residual vegetation >5 mm has an increased 
associated risk of stroke compared with patients without a residual vegetation. These findings 
provide new perspectives on a patient group sparsely describe, suggesting a potential benefit of 
therapy among patients surviving IE with a residual vegetation >5 mm. 
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Figure legends 
Figure 1. Patient selection process 
Figure 1. The figure shows a flow chart of the patient selection. 
IE: infective endocarditis. 
Figure 2. Cumulative incidence of stroke 
Figure 2. The figure shows the cumulative incidence of stroke for patients without residual 
vegetation, 1-5 mm residual vegetation, and >5 mm residual vegetation. 
Figure 3. Associated risk of stroke 
Figure 3. The figure shows the associated risk of stroke for patients with 1-5 mm residual 
vegetation and >5 mm residual vegetation compared with patients without residual vegetation in a 
crude and multivariable adjusted regression model. The multivariable adjusted analysis was 
adjusted for: prior IE, prosthetic heart valve, microbiologic etiology, sex, age, chronic renal 
impairment, native valve disease. 
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Table 1. Baseline characteristics  
 No residual 
vegetation 
1-5 mm 
residual 
vegetation 
>5 mm residual 
vegetation 
p-value 
Demographics     
   Number 151 73 81  
   Male, n (%) 106 (70.2) 42 (57.5) 63 (77.8) 0.07 
   Age (years), median (IQR) 68.0 (56.0-78.0) 70.0 (64.0-77.0) 68.0 (60.0-78.0) 0.49 
   TEE at discharge, n (%) 144 (95.4) 70 (95.9) 78 (96.3) 0.94 
   Length of residual vegetation, median in mm (IQR) - 4 (2-5) 8 (7-10)  
Comorbidity, medical history prior to IE, n (%)     
   Pacemaker 12 (8.0) 7 (9.6) 8 (10.0) 0.85 
   Chronic renal impairment 19 (12.6) 12 (16.7) 13 (16.3) 0.63 
   Diabetes mellitus 18 (11.2) 17 (23.3) 12 (14.8 0.086 
   Cancer at admission 11 (7.4) 6 (8.2) 9 (11.1) 0.62 
   Neurologic disease 20 (13.3) 7 (9.6) 10 (12.4) 0.80 
   Atrial fibrillation 46 (30.5) 22 (30.1) 14 (17.3) 0.075 
   Antihypertensive medication* 60 (39.7) 48 (65.8) 34 (42.0) 0.001 
Predisposing conditions, n (%)     
   Native valve disease 21 (14.1) 13 (18.1) 16 (20.0) 0.66 
   Prosthetic valve  69 (46.0) 22 (31.0) 23 (29.1) 0.017 
   Previous IE 14 (9.5) 4 (5.6) 7 (8.8) 0.60 
   Intravenous drug abuse 5 (3.3) - - 0.27 
   Immunosuppressant therapy 15 (10.2) 11 (15.7) 6 (7.6) 0.27 
Site of infection, n (%)    0.009 
   Aortic 81 (53.6) 27 (37.0) 32 (39.5)  
   Mitral 57 (37.8) 28 (38.4) 33 (40.7)  
   Aortic and mitral 13 (8.6) 18 (24.7) 16 (19.8)  
Microbiologic finding, n (%)    0.47 
   Hemolytic streptococci 36 (23.8) 23 (31.5) 18 (22.2)  
   Enterococcus faecalis 41 (27.2) 13 (17.8) 15 (18.5)  
   Staphylococcus aureus 24 (15.9) 15 (20.6) 21 (25.9)  
   CoNS 10 (6.6) 4 (5.5) -  
   Non-hemolytic streptococci 12 (8.0) 5 (6.9) 5 (6.2)  
   Blood culture negative 9 (6.0) 7 (9.6) 9 (11.1)  
   Other 19 (12.6) 6 (8.2) 13 (16.0)  
IE: infective endocarditis, IQR: interquartile range, CoNS: Coagulase negative staphylococci, mm: milimeter. 
**Defined as at least two drugs of antihypertensive medication (see Supplementary Table 1) 
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Highlight 
 We linked the East Danish Endocarditis Registry with nationwide registries. 
 A total of 305 patients surviving infective endocarditis were included. 
 Residual vegetation was assessed with echocardiography at discharge. 
 Patients with >5 mm vegetation were associated with increased risk of stroke. 
 No difference in the associated risk of recurrence of IE or mortality was seen. 
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